Belapectin Phase 3 Advances
FDA Backs Galectin Therapeutics' Belapectin Phase 3 Plan for MASH Cirrhosis and Portal Hypertension
Anonymous
Key Points
1
Financial and insider-trading context for Galectin Therapeutics: GF Score™ is listed as 16/100, indicating notable financial-strength and profitability challenges; the company showed 1 insider selling transaction in the last 3 months with no insider buying, and a reported market capitalization of about $184.4 million.
2
The primary endpoint in the Phase 3 program will be a composite liver outcome that includes prevention of large esophageal varices, specifically those greater than 5 mm in diameter.
3
FDA acceptance of a blinded central review process for endoscopic assessment of esophageal varices, designed to be standardized across sites and aligned with the NAVIGATE trial’s methodology to ensure rigorous evaluation of outcomes.
4
The company emphasized the substantial unmet medical need in patients with MASH cirrhosis and portal hypertension, noting these patients are at high risk of life-threatening decompensation and are currently excluded from enrolling in other ongoing drug development efforts.
Galectin Therapeutics announced Monday that the FDA has aligned with the company on the Phase 3 trial design for belapectin, a drug targeting liver disease in patients with MASH cirrhosis and portal hypertension. Shares surged on the news, according to MarketWatch, though the stock still fell roughly 9% in premarket trading as investors weighed the long road ahead.
The FDA agreed on a composite liver outcome as the primary endpoint, including prevention of large esophageal varices — dilated veins in the esophagus that can rupture and cause life-threatening bleeding. Galectin plans to file the final Phase 3 protocol in Q3 2026, Nasdaq reported.
FDA Green-Lights a Clear Path to Full Approval
The FDA confirmed a traditional full approval pathway for belapectin, Investing.com reported. That means Galectin cannot rely on surrogate markers — like liver biopsy results — for accelerated approval. The company must prove a real clinical outcome: that the drug prevents large esophageal varices, specifically those greater than 5 mm in diameter.
The FDA also accepted a blinded central review process for endoscopy. That means a consistent panel of experts — not individual site doctors — will assess varices across all trial sites. This approach mirrors the methodology used in the NAVIGATE trial and reduces variability in how outcomes are measured, according to GuruFocus.
NAVIGATE Data Drove the Phase 3 Decision
The Phase 3 plan builds on Galectin's Phase 2b NAVIGATE trial. The trial missed its primary endpoint in the full patient population. But in patients who strictly followed the 18-month treatment, the 2 mg/kg dose cut variceal incidence from 22.3% in the placebo group to 11.3% — a 43.2% numerical reduction, according to GuruFocus.
Those results were published in the journal Hepatology in May 2026 and presented at the EASL 2026 Congress in Amsterdam. The data showed significant reductions in liver stiffness and a key fibrosis marker called Pro-C3. CEO Joel Lewis said FDA "acknowledged the substantial unmet medical need" in this patient population during the meeting.
Patients With MASH Cirrhosis Are Left Out Everywhere Else
MASH — metabolic dysfunction-associated steatohepatitis — is an advanced form of fatty liver disease. When it progresses to cirrhosis, scar tissue builds up and raises pressure in the portal vein. That pressure creates esophageal varices. Galectin is targeting patients who already have cirrhosis and portal hypertension but have not yet developed large varices.
This population is currently excluded from most other MASH drug trials, which focus on earlier-stage patients. Galectin management called the unmet need "substantial." About 2.6% of the U.S. population has cirrhosis, and MASH is now the leading cause of liver transplants in women, MarketWatch reported.
Galectin Needs a Partner — and Fast
Galectin carries a GF Score of 16 out of 100, signaling serious financial and profitability challenges, according to GuruFocus. The company has a market cap of about $184.4 million, zero revenue, and a cash runway projected only to April 2027. One insider sold shares in the last three months. No insider bought.
Management said it is "actively exploring strategic and financial partnership opportunities" to fund the capital-intensive Phase 3 trial. Some analysts hold price targets as high as $11 per share, citing the large untapped MASH cirrhosis market. But until a partner signs on, the timeline to Phase 3 launch remains uncertain, Nasdaq reported.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
27
Reach
39
A
AnonymousAuthor
